Want to join the conversation?
$LGND partner $RTRX said Phase 2 DUET study achieved statistical significance in the primary efficacy endpoint for the overall sparsentan treatment group, demonstrating a greater than two-fold reduction of proteinuria compared to irbesartan after the eight-week, double-blind treatment period.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.